LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Chief Executive Officer, President and Chairman, Kevin Hrusovsky, will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, January 10, at 2:30 p.m. PST (5:30 p.m. EST) at the Westin St. Francis Hotel in San Francisco.
To access the live webcast of Quanterix’ presentation please visit the News & Events page within the Investors section of the Quanterix website at www.quanterix.com. Replays of the webcast will be available on the Quanterix website for 60 days following the conference.
About Quanterix
Quanterix is a company that’s digitizing
biomarker analysis with the goal of advancing the science of precision
health. The company’s digital health solution, Simoa, has the potential
to change the way in which healthcare is provided today by giving
researchers the ability to closely examine the continuum from health to
disease. Quanterix’ technology is designed to enable much earlier
disease detection, better prognoses and enhanced treatment methods to
improve the quality of life and longevity of the population for
generations to come. The technology is currently being used for research
applications in several therapeutic areas, including oncology,
neurology, cardiology, inflammation and infectious disease. The company
was established in 2007 and is located in Lexington, Massachusetts. For
additional Information, please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as "may," "will," "expect,"
"plan," "anticipate," "estimate," "intend" and similar expressions (as
well as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this news release include, but are not
limited to Simoa’s potential ability to change the way in which
healthcare is provided today and the ability of Quanterix’ technology to
enable much earlier disease detection, better prognoses and enhanced
treatment methods, and are based on Quanterix’ expectations and
assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Factors
that may cause Quanterix’ actual results to differ from those expressed
or implied in the forward-looking statements in this press release are
discussed in Quanterix’ filings with the U.S. Securities and Exchange
Commission, including the "Risk Factors" sections contained therein.
Except as required by law, Quanterix assumes no obligation to update any
forward-looking statements contained herein to reflect any change in
expectations, even as new information becomes available.